Dr. Ibiayi Dagogo-Jack

About Dr. Dagogo-Jack

Dr. Dagogo-Jack leads the mesothelioma program at Mass General Cancer Center. She focuses her clinical and research efforts on mesothelioma and thoracic cancers, including developing novel drug combinations and targeted therapies. Her work centers on understanding why some cancers resist treatment and how to overcome that resistance. 

She combines cutting-edge science with personalized patient care to improve outcomes for people diagnosed with mesothelioma. This patient-centered approach has earned her respect as a specialist who guides people through complex treatment choices with compassion and expertise.

Close Button

Full Name

Diagnosis Please Select Mesothelioma Asbestosis Lung Cancer No Diagnosis Other Unknown

Zip Code

Email

Phone Number

Preferred Method of Contact Please Select Call Text

Message

Full Name

By submitting, you agree to our privacy policy and terms of service. Our Patient Advocates may contact you via phone, email and/or text.

Get Connected Now

Medical Education & Expertise

• Massachusetts General Cancer Center
• Dana-Farber Cancer Institute (Fellowship)
• Brigham and Women’s Hospital (Residency)
• University of Chicago Pritzker School of Medicine (M.D.)
• Vanderbilt University (B.A.)

Associations, Awards & Recognition

• Alpha Omega Alpha Inductee, 2011
• Associate Professor of Medicine, Harvard Medical School
• Fellow of the American Society of Clinical Oncology Award, 2025
• GRACE Patient Educator of the Year, 2022
• Member, American Board of Internal Medicine

Why Choose Dr. Dagogo-Jack for Mesothelioma?

Dr. Dagogo-Jack offers mesothelioma patients expert care focused on targeted and immunotherapies. Her research into drug resistance and clinical trials means patients can access the latest treatments. She prioritizes personalized, compassionate care to help people navigate complex decisions about their treatment.

Her role at one of the nation’s leading cancer centers ensures multidisciplinary support for each person diagnosed with mesothelioma. Patients benefit from her deep expertise, collaborative approach and focus on improving survival and quality of life.

Publications of Dr. Dagogo-Jack

Ibiayi Dagogo-Jack et al. (2025, October). Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40480428/

Ibiayi Dagogo-Jack et al. (2025, January). Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39615410/

Ibiayi Dagogo-Jack et al. (2024, November). Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39802817/

Ibiayi Dagogo-Jack et al. (2020, December). The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33489818/

Ibiayi Dagogo-Jack. (2020, October). Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32981611/